-
Three Biotech Stocks Analysts Are Keen On (ARIA, MACK, GEVA)
Wednesday, October 3, 2012 - 2:57pm | 549Read More...Here is a quick look at three top-performing biotech stocks, each with a consensus recommendation (among analysts) of Strong Buy. They are Ariad Pharmaceuticals (NASDAQ: ARIA), Merrimack Pharmaceuticals (NASDAQ: MACK) and Synageva BioPharma (NASDAQ: GEVA). Ariad Pharmaceuticals Shares of this...
-
Piper Jaffray Comments On Affymax 4Q Earnings
Friday, March 11, 2011 - 8:49am | 181Read More...In a report published by Piper Jaffray, Affymax's (NASDAQ: AFFY) NDA is expected in 2Q11. Piper Jaffray said that Affymax reported 4Q10 EPS of ($0.46), which was a $0.25 greater loss than its estimate of ($0.21). “The loss was primarily driven by lower than projected revenue. We continue to expect...
-
Auriga Reiterates Hold on Affymax
Monday, November 8, 2010 - 11:07am | 87Read More...Auriga has published a research report this morning on Affymax, Inc. regarding 3Q10 Results. Auriga writes, "Affymax (NASDAQ: AFFY) reported 3Q10 results on Friday that were essentially a nonevent. The key focus for AFFY investors is gaining further clarity on the next steps in the Hematide...
-
AFFY Appealing To Federal Court Over IP Dispute With JNJ
Monday, October 11, 2010 - 8:05am | 238Read More...Auriga USA has published a research report on Affymax, Inc. (NASDAQ: AFFY) following the announcement of its co-ownership of certain intellectual property with Johnson & Johnson (NYSE: JNJ). In the report, Auriga writes "AFFY announced the arbitration panel reviewing its IP dispute with Johnson...
-
New Price Target For AFFY
Monday, October 4, 2010 - 9:50am | 26Read More...Argus reiterates its Buy rating for Affymax Inc. (NASDAQ: AFFY) but has lowered the price target from $30 to $15.
